We utilized data from eight RCTs with participant clinical, outcome and genetic data [56,57,58,59,60,61,62] (Table 1 and Supplemental Digital Contents 1–4: Randomized clinical trial design characteristics; Behavioral and demographic variables selected for analysis; Inclusion and exclusion criteria for eight RCTs; Pharmacotherapy and behavioral therapy to EOT and 6MO of eight RCTs by randomization arm). The individuals included in the analysis represented 44% of individuals randomized to treatment in the eight RCTs, and 81% of individuals for whom we had received RCT data and biospecimens or DNA samples. Reasons for exclusion include: 1) a biospecimen was not collected [1595 (27.0%)]; 2) did not self-identify as White [1168 (19.7%)]; 3) were randomized to pharmacotherapy arms not selected for this analysis [490 (8.3%)]; 4) did not enter treatment after randomization [188 (3.2%)]; 5) DNA sample genotype completion rate was below a predetermined threshold [70 (1.2%)]; and/or chromosomal sex did not match clinical gender [22 (0.4%)].
